NR3C2 and Hyperkalemia: As such, concerns about the occurrence of hyperkalemia during therapy are growing, but there is a lack of understanding and guidance about the appropriate management of hyperkalemia during antihypertensive therapy with MR blockers, especially with the newer agent esaxerenone.